Duration of Use Among New Users of Hydrochlorothiazide (HCTZ), Angiotensin-Converting Enzyme Inhibitors (ACEIs), and Angiotensin II Receptor Blockers (ARBs)

Details

Basic Details

Date Posted

Friday, April 19, 2019

Status

Complete

Medical Product

angiotensin II receptor blocker (ARB)

angiotensin-converting enzyme (ACE) inhibitor

hydrochlorothiazide (HCTZ)

Description

This report contains estimates of hydrochlorothiazide (HCTZ), angiotensin-converting enzyme inhibitor (ACEI), and angiotensin II receptor blocker (ARB) utilization in the Sentinel Distributed Database (SDD). Data from January 1, 2000 to June 30, 2018 from 17 Data Partners contributing to the SDD were included in this report. This request was distributed to Data Partners on August 20, 2018.

Deliverables (1)

Sentinel Modular Program Report: Hydrochlorothiazide (HCTZ), Angiotensin-Converting Enzyme Inhibitor (ACEI), and Angiotensin II Receptor Blocker (ARB) Utilization

Additional Information

Additional Details

FDA Center

CDER

Time Period

January 1, 2000 - June 30, 2018

Analysis Type

Descriptive

Population / Cohort

All individuals

Data Sources

Sentinel Distributed Database (SDD)